ArticleDigestive diseases and sciences2026
Prevalence of Gastric Intestinal Metaplasia Among Patients with Active Helicobacter Pylori Infection Served by a Safety-Net Healthcare System.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
backgroundGastric intestinal metaplasia (GIM) is a precursor of gastric cancer. Prior estimates of GIM prevalence in retrospective studies of U.S. populations may not be representative of true prevalence because gastric biopsies are not routinely performed for screening in the general population.
methodsParticipants from a cross-sectional screening study of a safety-net patient population in Houston, Texas, who were Helicobacter pylori seropositive underwent endoscopy with systematic gastric mapping biopsies per Sydney protocol. Among participants with histopathologic evidence of active H. pylori, we calculated the prevalence of GIM overall and within subgroups. We additionally examined the prevalence of extensive (body involvement) and severe (Operative Link on GIM Assessment [OLGIM] stage III/IV) GIM.
resultsWe included data from 273 patients with mean age 47.4 years. Most patients were female (75.1%), Hispanic (92.3%), and first-generation immigrants (90.5%). Overall, 28.9% (95% confidence interval [CI] 23.6%-34.7%) of patients with active H. pylori had GIM, including 8.1% (95% CI 5.1%-11.9%) with extensive GIM. All participants with GIM had OLGIM stage I/II. Prevalence of GIM did not vary between sociodemographic groups. Prevalence of GIM was 29.0% (95% CI 23.4%-35.0%) among Hispanic patients and 28.6% (95% CI 11.3%-52.2%) among non-Hispanic patients. GIM prevalence among first-generation immigrants (28.7%; 95% CI 23.2%-34.4%) was similar to among second- and third-generation immigrants (30.8%; 95% CI 14.3%-51.8%).
conclusionsIn a safety-net U.S. population, 28.9% of patients with active H. pylori infection had GIM. While GIM may improve after H. pylori eradication, prevalence of GIM is high in all sociodemographic subgroups in the setting of active H. pylori infection.
Indexed as
Identifiers
42789143What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.